Skip to main content

Special Feature Fifth Annual Payers' Guide to New FDA Approvals March 2014 Volume 7

View Digital Edition

Brintellix Tablets (Vortioxetine) Approved by the FDA for the Treatment of Major Depressive Disorder

Gazyva (Obinutuzumab) for Chronic Lymphocytic Leukemia: First FDA-Approved Breakthrough Therapy in Oncology

Lisa A. Raedler, PhD, RPh

Fetzima Extended-Release (Levomilnacipran) Receives FDA Approval for the Treatment of Major Depressive Disorder in Adults

Gilotrif (Afatinib): Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation

Lisa A. Raedler, PhD, RPh

Ilaris (Canakinumab) Receives a New Indication for the Treatment of Systemic Juvenile Idiopathic Arthritis

Lisa A. Raedler, PhD, RPh

Imbruvica (Ibrutinib) for Mantle-Cell Lymphoma: First Bruton’s Tyrosine Kinase Inhibitor Approved for Use in a Hematologic Malignancy

Lisa A. Raedler, PhD, RPh

Injectafer (Ferric Carboxymaltose Injection) Receives FDA Approval for the Treatment of Iron-Deficiency Anemia

Invokana (Canagliflozin): First-in-Class SGLT2 Inhibitor Approved for the Treatment of Type 2 Diabetes

Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer

Lisa A. Raedler, PhD, RPh

Mirvaso (Brimonidine): First Topical Gel Approved by the FDA for the Treatment of Facial Erythema of Rosacea

Page 2 of 4
Results 11 - 20 of 33